Council member company, Cellumen, Inc. – a leading innovator in cellular systems biology – recently made an exciting announcement. Check it out!
Cellumen, Inc., a discovery toxicology company, today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), one of the leading pharmaceutical companies in Japan, to develop panels of biomarkers that identify toxicity early in the drug development process.
“We’re pleased to announce this collaboration with MTPC,” says D. Lansing Taylor, PhD, CEO of Cellumen. “By working together to develop biomarker panels, we hope to identify toxic liabilities much earlier in the drug development process than currently exists in the marketplace. Our ultimate goal is to enable MTPC to prioritize its lead drug series.”
Cellumen is focused on decreasing the drug attrition rate due to toxicity. The company’s CellCiphr® CSBTM Toxicity Profiling Services can identify toxic compounds in late primary screening through early pre-clinical phases, before entering expensive pre-clinical testing where the pharmaceutical industry is losing millions of dollars from drugs that do not meet the FDA’s safety requirements. By integrating optimal cells, panels of functional biomarkers and classifier software, CellCiphr is able to create a Safety Risk Index for compounds, and help researchers predict potential rodent or human toxicity earlier than ever before.
|
||||||
